The US FDA recently gave priority review designation and subsequently approved the combination of ceftolozane and tazobactam, assisting in the treatment of Hospital-acquired bacterial pneumonia (HABP) and Ventilator-associated bacterial pneumonia (VABP) for patients with 18 years of age and above. The combination was earlier approved for treating complicated urinary tract infections and intra-abdominal infections, the same combination is approved for a new indication related to HABP or VABP. HABP or VABP is hospital related infections caused by various species of gram-negative pathogenic bacteria.
It is one of the most serious issues in the Intensive care unit (ICU). It is primarily caused by Enterobacter cloacae, Proteus mirabilis, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Serratia marcescens. Drug Information: Parameter Ceftolozane Tazobactam General…
